|

Lutathera Clinical Trials

1 actively recruiting trial

▼ -1 trial since August 2026

Also known as: (Lu 177)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10- tetraazacyclododec-1-yl) acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-Lcysteinyl-L-threonine-cyclic (2-7) disulfide., 177 Lu-DOTA-octreotate, lutetium Lu 177 dotatate

Pipeline

Phase 2: 1

Top Sponsors

  • Institut du Cancer de Montpellier - Val d'Aurelle1

Indications

  • Progressive Disease1
  • Intestinal Well Differentiated Endocrine Tumor1
  • Neuroendocrine Tumors1
  • Cancer1

Other1 trial

Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.